Harvard Bioscience will announce its Q4 2024 financial results on March 12, 2025, followed by a conference call.
Quiver AI Summary
Harvard Bioscience, Inc. will release its financial results for the fourth quarter of 2024 on March 12, 2025, before the market opens, and will host a conference call at 8:00 a.m. Eastern Time to discuss these results. Participants interested in asking questions during the call must register to receive dial-in numbers and a unique PIN. An audio-only webcast will also be available through the company’s investor website. Financial information, including the earnings release and a slide presentation, will be accessible in the Investor Relations section of the website. Harvard Bioscience develops and sells technologies and services for life science applications globally, serving a variety of prominent customers in research and pharmaceutical development.
Potential Positives
- Harvard Bioscience, Inc. will announce its financial results for Q4 2024, indicating transparency and proactive communication with stakeholders.
- The scheduled conference call for discussing financial results demonstrates the company's commitment to engaging with investors and analysts.
- The availability of financial information through the investor relations website highlights the company’s focus on accessibility and transparency in its financial reporting.
- Harvard Bioscience's diverse customer base, including leading academic institutions and pharmaceutical organizations, underscores its strong market position and relevance in the life sciences industry.
Potential Negatives
- The upcoming financial results announcement may indicate that the company is facing scrutiny, as it signals the need for transparency regarding its recent performance, which could be a concern for investors.
- The requirement for participants to register to ask questions during the conference call may limit open communication and transparency, potentially raising concerns among shareholders and analysts.
FAQ
When will Harvard Bioscience announce its financial results?
Harvard Bioscience will announce its financial results on March 12, 2025, before market opening.
How can I join the conference call for Harvard Bioscience's results?
Participants can register to join the call and ask questions. Registration is required to receive dial-in numbers and a unique PIN.
Is there an audio-only option for the conference call?
Yes, participants can join the audio-only webcast through the events and presentations section on the investor website.
Where can I find the financial information presented during the call?
The financial information, including the earnings release and slide presentation, will be available in the Investor Relations section of the Harvard Bioscience website.
What services does Harvard Bioscience provide?
Harvard Bioscience develops and sells technologies for life sciences applications, including research and pharmaceutical development.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HBIO Hedge Fund Activity
We have seen 46 institutional investors add shares of $HBIO stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- 272 CAPITAL LP added 758,685 shares (+128.0%) to their portfolio in Q4 2024, for an estimated $1,600,825
- ROYCE & ASSOCIATES LP added 513,664 shares (+35.4%) to their portfolio in Q4 2024, for an estimated $1,083,831
- RUSSELL INVESTMENTS GROUP, LTD. removed 298,300 shares (-99.0%) from their portfolio in Q4 2024, for an estimated $629,413
- GRANAHAN INVESTMENT MANAGEMENT, LLC removed 248,251 shares (-13.3%) from their portfolio in Q4 2024, for an estimated $523,809
- BOSTON PARTNERS removed 207,326 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $557,706
- BOOTHBAY FUND MANAGEMENT, LLC removed 184,423 shares (-13.8%) from their portfolio in Q4 2024, for an estimated $389,132
- GLOBEFLEX CAPITAL L P removed 139,514 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $375,292
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Participants who would like to join the call and ask a question must register
here
. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website
here
.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at
www.harvardbioscience.com
.
Company Contact:
Jennifer Cote
Chief Financial Officer
(508) 893-3120
Investors Contact:
Three Part Advisors
Sandy Martin
HBIO@threepa.com
(214) 616-2207
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
